Wendy Blanda, Phd

Wendy Blanda, Phd Email and Phone Number

Pharmaceutical Chemistry & Manufacturing Controls Consultant Providing Elegant Solutions @ 3Daughters
Wendy Blanda, Phd's Location
Tustin, California, United States, United States
Wendy Blanda, Phd's Contact Details
About Wendy Blanda, Phd

I hold a PhD from the University of Michigan in Macromolecular Science and Engineering as well as 20+ year industry record of concept-to-launch success within challenging drug-device combination product systems. I am currently transitioning my vast industry experience into a consulting practice with focus on 4 core services:FORMULATION SCIENCE I manage formulating, analytical testing, process development, and manufacturing – the chemistry and manufacturing control (CMC) system. I have a vision for what the FDA and EMA need in the regulatory filing. I put the pieces of the story together so the filing (IND, NDA, or CTD) shows the FDA or EMA that the product is well understood and safe for patients. I also manage from Clinical Phase 1 through commercialization, with clearly understood and tested changes to the product or the process. CMC TEAM LEADERSHIP AND CMC REGULATORY I am an enthusiastic CMC team leader. I have assembled and managed CMC teams in both large and small companies. My style of management encourages transparency and responsibility. I develop teams that are passionate about their contribution to the project. The guiding beacon for the team is always the regulatory filing. I develop a strategy for what pieces will go into the CMC sections, what questions might be asked by authorities, and what is phase appropriate. I represent the CMC team in meetings with regulatory authorities and devise concise responses.R&D OUTSOURCE MANAGEMENT CONSULTANT I outsource pieces of the project and manage vendors. I use companies’ expertise and equipment to benefit the project. I identify the right contractors, building and managing relationships, and managing costs/timelines. I also source raw materials and packaging needed for the project. On the other end of the spectrum, when in-house capabilities need to be increased, I source new equipment and laboratory space. SUSTAINED RELEASE IMPLANTS My expertise is sustained release implants, such as when drug needs to be delivered to a specific area of the body for an extended period of time. My main experience is with ocular implants and vaginal drug delivery, but the concepts are applicable to other areas, such as subdermal and transdermal delivery systems. I am considered a subject matter expert in these complex areas and I’m often requested to give my scientific opinion that guides the project.My scientific background blended with my project management skills and my authentic and servant leadership approach maximizes the value I bring to companies for best-in-class results.

Wendy Blanda, Phd's Current Company Details
3Daughters

3Daughters

View
Pharmaceutical Chemistry & Manufacturing Controls Consultant Providing Elegant Solutions
Wendy Blanda, Phd Work Experience Details
  • 3Daughters
    Acting Senior Director, Product Development
    3Daughters Oct 2023 - Present
    Mansfield, Ma, Us
    CMC consulting and leadership on a groundbreaking IUD, custom inserter, and custom retriever. Drug-device combination product development, testing, stability, and clinical trial supplies manufacturing
  • Atheln, Inc.
    Consultant, Development & Manufacturing, Combination Products
    Atheln, Inc. Feb 2023 - Present
    San Diego, Ca, Us
    Atheln helps clients create and execute integrated pharma and biotech product development and commercialization strategies. Their global team of over 100 highly specialized, industry-seasoned experts excel at risk identification and mitigation, while delivering phase appropriate and customized solutions that increase value and likelihood of success.
  • Blanda And Associates, Llc
    Company Owner / Principal Consultant
    Blanda And Associates, Llc Jan 2023 - Present
    - Formulation development troubleshooting- CMC team staffing and leadership- CMC regulatory interaction and regulatory agency interactions- IND, NDA, and eCTD technical writing- CDMO, CRO, CMO, and contract analytical testing lab selection and oversight - Laboratory facility design and sourcing- Quality audit technical resource- Product failure root cause analysis and CAPA implementation- Intellectual property and patent claim generation- Project management- Nonclinical program strategies and protocol implementation- Drug-Device combination products- Design controls- Excipient selection and sourcing- Process chemistry contract management- Critical quality attribute (CQA) identification- Quality by design (QBD) implementation- Phase appropriate planning- FDA and EMA interactions- Analytical method development and validation
  • Spyglass Pharma, Inc.
    Director, Drug Delivery
    Spyglass Pharma, Inc. Sep 2019 - Mar 2022
    Aliso Viejo, California, Us
    Responsible for establishing drug-device product development strategy and leading a team of scientists and engineers for all stages of programs ranging from preclinical GLP studies through Phase 3 clinical trials. Accountable for ensuring that overall operational budget was within the approved range and timeline, developed project plans, execution strategies, hired junior and senior scientists, and communicated project updates to Board of Directors (BOD). • Conducted the development, transfer, automation, and qualification of manufacturing processes for drug products used in GLP non-clinical and cGMP clinical development. • Developed the 505 b (2) bridging strategy, including PK, PD, and Tox studies, resulting in two positive pre- investigational new drug (pIND) meetings with the FDA and single species GLP-Tox testing.• Saved $1 M by recommending and executing technical transfer of development between Contract Drug Manufacturing Operation (CDMO’s).• Oversaw SOP’s, IOQ protocols/reports, BPR’s, specifications, risk assessments, and other documentation for CMC activities. • Led the in-house and sub-contracted analytical teams, including the method development and validation of bioanalytical assays, sustained release assay, sterility, assay, elemental analysis, and physical testing. Established product specifications based on statistical analysis.A strong understanding of CFR Parts 58, 210, and 211; ICH; and FDA regulatory guidance related to Extensive experience with development and optimization of manufacturing processes and oversight of manufacturing campaigns for supplies ranging from GLP toxicology supplies to cGMP Phase 3 clinical trial material• Excellent interpersonal verbal, written and presentation skills in communication with internal and external customers
  • Spyglass Ophthalmics
    Director, Drug Delivery
    Spyglass Ophthalmics Sep 2019 - Mar 2022
    Gained $27.5 M series B funding by showing proof of concept of primary product and six pipeline products.Established and oversaw the implementation of the overall CMC strategy for all stages of programs ranging from preclinical GLP studies through Ph3 clinical trials•Directly managed and oversaw all CMC activities •Led the development, transfer, automation and qualification of manufacturing processes for drug products for use in GLP non-clinical and cGMP clinical development•Led outsourcing of manufacturing activities and negotiations•Led and oversaw SOPs, IOQ Protocols/Reports, BPRs and Specifications for CMC activities•Analyzed and summarized complex data sets, including the use of appropriate statistical tools for the identification of CPPs and CQAs, development of drug product specifications and shelf-life estimates for drug product formulations•Reviewed CMC project plans and timelines and assist in execution to ensure all projects are appropriately prioritized and key goals are met on time•Developed and maintained an in-depth knowledge of drug product manufacturing and development technology; and the associated regulatory requirements•Authored and reviewed CMC regulatory submissions•Communicated project status and concerns to management and project leadership•Effectively worked with cross-functional team leaders to achieve corporate and program goals•Ensured overall operational budget is within the approved budget and timeline
  • Titan Pharmaceuticals
    Director, Chemistry And Manufacturing Controls
    Titan Pharmaceuticals Jun 2019 - Sep 2019
    South San Francisco, California, Us
    Accountable for development of sustained release sub-dermal implants, formulation design and development for all cGMP drug products. Wrote and reviewed technical source documents for regulatory submissions. • Managed development of a DEA Class 1 controlled substance drug product at contract manufacturing organizations (CMO’s), including project management, vendor management, site visits, and technical expert decision making. • Received $8.7M in government grant by developing and executing plans for validation and registration of drug products as required by cGMP, ICH, and FDA/EMEA regulations.
  • International Partnership For Microbicides
    Associate Director - Formulation Technologies
    International Partnership For Microbicides Dec 2015 - Jun 2019
    Served as team leader and subject matter expert for pre-formulation and formulation development activities for six pipeline projects, ranging from pre-clinical through commercialization stage. • Oversaw the RFP selection and oversight process for outsourcing of formulation development of silicone and thermoplastic vaginal rings for the developing world. Negotiated milestone payment contracts, material transfer agreements, and confidentiality agreements.• Received EMA and WHO product approval by communicating with the EMA to responding to questions regarding Module 3 of the eCTD for the dapivirine vaginal ring for HIV prevention.• Identified a key drug-excipient incompatibility. Once resolved, drug assay increased from 60% to 95%, saving Cost of Goods (COG) and reducing patient risk.International Partnership for Microbicides, Silver Spring, MD, cont. • Developed system for and implemented design history file, design reviews, and risk assessment for drug-device combination products (ISO 14971, ISO 13485, ISO 13578). • Presented to the board of directors (BOD) and scientific advisory board (SAB), including the Bill and Melinda Gates foundation, Population Council USAID and other donors and collaborators.
  • International Partnership For Microbicides
    Senior Manager - Formulation Technology
    International Partnership For Microbicides Dec 2013 - Dec 2015
  • Allergan, Inc.
    Senior Scientist
    Allergan, Inc. 2003 - Dec 2013
    Dublin, Coolock, Ie
    Manager and Formulator in newly established Drug Delivery Research group. CMC team leader for two pre-clinical stage projects. Responsible for cross-functional team management of junior scientists for early-stage products including small molecule, peptide, and protein therapeutic agents. • Established strategy for development of two sustained release products, from pre-clinical through Phase 2.• Contributed and reviewed chemistry and manufacturing controls input for IND’s and NDA’s. • Advanced products from lab scale proof of concept stage to GLP and GMP manufacturing. • Formulated and analyzed oligonucleotides, monoclonal antibodies, peptides, alpha-2 agonists, tyrosine kinase inhibitors, SiRNA’s, NSAID’s, immunosuppressants, glucocorticoid steroids, and other compounds for intraocular sustained release drug delivery. • Developed injectable rod, colloid, emulsion, suspension, microsphere, slurry suspension, sterile gel, lyophilized powder in-situ gelling and organic solvent based injectables of biocompatible polymers resulting in reduction to practice for multiple patents, greatly enhancing Allergan’s ocular patent space.Led the technology transfer and set-up of Allergan’s first sustained release drug delivery system innovation space, resulting in the training of over 50 scientific personnel and launch of two commercial products. Formulator and CMC team member for multiple drug-device products, from pre-clinical to product launch.
  • Oculex, Inc.
    Senior Scientist, Formulations Development
    Oculex, Inc. 2001 - 2003
    Optimized Ozurex™ Phase 2B/Phase 3 process scale-up design of experiments (DOE) for startup specialty pharmaceutical firm. Collaborated in design/build of custom extrusion systems for drug-device product manufacturing. Led process development and scale-up team. Transferred formulation and manufacturing processes from Oculex to Allergan post-acquisition.
  • Jds Uniphase
    Engineer, Fiber Optic Products
    Jds Uniphase 2000 - 2001
    Polymer specialist for submarine components and high reliability research group. Performed failure analysis for fused fiber device based on polymer performance degradation, reporting results to global customers and implementing solutions in manufacturing.
  • University Of Michigan
    Graduate Student Instructor
    University Of Michigan 1995 - 2000
    Ann Arbor, Michigan, Us
    Taught general, organic, and physical chemistry classes/lab sections to undergraduates. Tutored students individually and in small groups.

Wendy Blanda, Phd Skills

Drug Delivery Technology Transfer Formulation R&d Drug Development Pharmaceutical Industry Gmp Biotechnology Fda Validation Life Sciences Clinical Development Drug Discovery Polymers Glp Biopharmaceuticals Product Development Chemistry Hplc Cmc Clinical Trials Analytical Chemistry Cross Functional Team Leadership Cro Management Chromatography Extrusion Lifesciences Regulatory Submissions Public Speaking Pharmacokinetics Regulatory Affairs Pharmaceutics Biomaterials Leadership Project Management Cro Management Good Laboratory Practice Engineering Management Outsourcing Manufacturing Operations Management Teaching Adults Interdisciplinary Collaboration Biodegradable Polymers Controlled Release Ocular Disease Virtual Collaboration Cross Team Collaboration Risk Management Drug Device Design Control

Wendy Blanda, Phd Education Details

  • University Of Michigan
    University Of Michigan
    Macromolecular Science And Engineering
  • California State University, Northridge
    California State University, Northridge
    Engineering Management
  • California Polytechnic State University-San Luis Obispo
    California Polytechnic State University-San Luis Obispo
    Polymer Chemistry

Frequently Asked Questions about Wendy Blanda, Phd

What company does Wendy Blanda, Phd work for?

Wendy Blanda, Phd works for 3daughters

What is Wendy Blanda, Phd's role at the current company?

Wendy Blanda, Phd's current role is Pharmaceutical Chemistry & Manufacturing Controls Consultant Providing Elegant Solutions.

What is Wendy Blanda, Phd's email address?

Wendy Blanda, Phd's email address is wb****@****hoo.com

What schools did Wendy Blanda, Phd attend?

Wendy Blanda, Phd attended University Of Michigan, California State University, Northridge, California Polytechnic State University-San Luis Obispo.

What are some of Wendy Blanda, Phd's interests?

Wendy Blanda, Phd has interest in Exercise, Home Improvement, Reading, Sports, Home Decoration, Health, Cooking, Electronics, Outdoors, Sewing.

What skills is Wendy Blanda, Phd known for?

Wendy Blanda, Phd has skills like Drug Delivery, Technology Transfer, Formulation, R&d, Drug Development, Pharmaceutical Industry, Gmp, Biotechnology, Fda, Validation, Life Sciences, Clinical Development.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.